Q32 Bio to Present at Needham Conference April 15; Webcast Available for 90 Days
Clinical-stage Q32 Bio will host a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 12:45 p.m. ET. Investors can access a live webcast and on-demand replay for 90 days on the company website, enhancing visibility for its Phase 2 anti-IL-7Rα alopecia areata antibody candidate bempikibart.
1. Event Details
Q32 Bio’s management team will participate in a fireside chat on April 15, 2026 at 12:45 p.m. ET during the 25th Annual Needham Virtual Healthcare Conference, marking its latest engagement with institutional investors and analysts.
2. Investor Access
The presentation will be streamed live on the Events and Presentations page of the Q32 Bio website, with an archived replay available for 90 days to allow broad investor access and ongoing visibility into the company’s strategy.
3. Pipeline Focus
Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody in Phase 2 trials for alopecia areata, targeting adaptive immune regulation to address a disease affecting roughly 700,000 U.S. patients with limited treatment options.